Page last updated: 2024-12-06

acifran

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

acifran: structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID51576
CHEMBL ID278488
SCHEMBL ID188221
MeSH IDM0111789

Synonyms (70)

Synonym
HMS3268E04
gtpl1595
acifran
reductol
ay-25712
reductol (tn)
72420-38-3
D02753 ,
acifran (usan/inn)
ay-25,712
2-furancarboxylic acid, 4,5-dihydro-5-methyl-4-oxo-5-phenyl-, (+-)-
4,5-dihydro-5-methyl-4-oxo-5-phenyl-2-furancarboxylic acid
2-furancarboxylic acid, 4,5-dihydro-5-methyl-4-oxo-5-phenyl-
acifran [usan:inn]
ay 25712
(+-)-4,5-dihydro-5-methyl-4-oxo-5-phenyl-2-furoic acid
acifranum [inn-latin]
(r,s)-4,5-dihydro-5-methyl-4-oxo-5-phenyl-2-furancarbonsaeure
CHEMBL278488 ,
acifranum
(+)-acifran
bdbm50208138
5-methyl-4-oxo-5-phenyl-4,5-dihydro-furan-2-carboxylic acid
5-methyl-4-oxo-5-phenyl-4,5-dihydrofuran-2-carboxylic acid
(-)-acifran
5-methyl-4-oxo-5-phenylfuran-2-carboxylic acid
unii-b1x701s0mv
b1x701s0mv ,
dtxsid9045685 ,
dtxcid7025685
tox21_110958
cas-72420-38-3
FT-0641407
2-furancarboxylic acid, 4,5-dihydro-5-methyl-4-oxo-5-phenyl-, (-)-
acifran (-)-form [mi]
fp3llw01bl ,
unii-61iz92gn57
77103-91-4
unii-fp3llw01bl
77103-92-5
acifran, (+)-
2-furancarboxylic acid, 4,5-dihydro-5-methyl-4-oxo-5-phenyl-, (+)-
61iz92gn57 ,
acifran, (-)-
acifran (+)-form [mi]
acifran [mart.]
2-furancarboxylic acid, 4,5-dihydro-5-methyl-4-oxo-5-phenyl-, (+/-)-
acifran [usan]
(+/-)-4,5-dihydro-5-methyl-4-oxo-5-phenyl-2-furoic acid
acifran [mi]
acifran [inn]
4,5-dihydro-5-methyl-4-oxo-5-phenylfuran-2-carboxylic acid
DFDGRKNOFOJBAJ-UHFFFAOYSA-N
AKOS022652744
SCHEMBL188221
NCGC00025283-02
tox21_110958_1
2-furancarboxylic acid,4,5-dihydro-5-methyl-4-oxo-5-phenyl-
5-methyl-4-oxo-5-phenyl-4,5-dihydro-2-furancarboxylic acid
SR-01000597500-1
sr-01000597500
HMS3676F16
HMS3412F16
Q15633960
ay 25712; acifran
(s)-1(3-bromophenyl)ethanamine
HMS3742C11
MS-23202
CS-0028902
HY-107579

Research Excerpts

Overview

Acifran is a well-known agonist of G-protein-coupled receptor protein, namely GPR109A.

ExcerptReferenceRelevance
"Acifran is a well-known agonist of G-protein-coupled receptor protein, namely GPR109A. "( Computational insights on molecular interactions of acifran with GPR109A and GPR109B.
Adepu, KK; Anishkin, A; Bhandari, D; Chintapalli, SV; Kachhap, S, 2022
)
2.41

Bioavailability

ExcerptReferenceRelevance
" Food reduced the bioavailability of acifran by 27% in the dog."( The metabolic disposition of acifran, a new antihyperlipidemic agent, in rats and dogs.
Cayen, MN; Dvornik, D; Ferdinandi, ES; Gonzalez, R; Greselin, E; Hicks, DR; Kraml, M, 1986
)
0.84
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (6)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
GLI family zinc finger 3Homo sapiens (human)Potency0.66820.000714.592883.7951AID1259369
cytochrome P450 family 3 subfamily A polypeptide 4Homo sapiens (human)Potency38.90180.01237.983543.2770AID1645841
estrogen nuclear receptor alphaHomo sapiens (human)Potency10.67170.000229.305416,493.5996AID743075
heat shock protein beta-1Homo sapiens (human)Potency0.21130.042027.378961.6448AID743210
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Hydroxycarboxylic acid receptor 3Homo sapiens (human)IC50 (µMol)3.00003.00003.00003.0000AID388795
Hydroxycarboxylic acid receptor 2Homo sapiens (human)IC50 (µMol)0.50000.13000.38891.5000AID388794
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Hydroxycarboxylic acid receptor 3Homo sapiens (human)EC50 (µMol)3.18320.31602.71904.2000AID1232300; AID281256; AID388795; AID428324
Hydroxycarboxylic acid receptor 2Homo sapiens (human)EC50 (µMol)0.91600.00871.20176.3096AID1232299; AID281255; AID388794; AID428325
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (5)

Processvia Protein(s)Taxonomy
G protein-coupled receptor signaling pathwayHydroxycarboxylic acid receptor 3Homo sapiens (human)
neutrophil apoptotic processHydroxycarboxylic acid receptor 2Homo sapiens (human)
positive regulation of neutrophil apoptotic processHydroxycarboxylic acid receptor 2Homo sapiens (human)
negative regulation of lipid catabolic processHydroxycarboxylic acid receptor 2Homo sapiens (human)
positive regulation of adiponectin secretionHydroxycarboxylic acid receptor 2Homo sapiens (human)
G protein-coupled receptor signaling pathwayHydroxycarboxylic acid receptor 2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (2)

Processvia Protein(s)Taxonomy
G protein-coupled receptor activityHydroxycarboxylic acid receptor 3Homo sapiens (human)
nicotinic acid receptor activityHydroxycarboxylic acid receptor 3Homo sapiens (human)
nicotinic acid receptor activityHydroxycarboxylic acid receptor 2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (2)

Processvia Protein(s)Taxonomy
plasma membraneHydroxycarboxylic acid receptor 3Homo sapiens (human)
cell junctionHydroxycarboxylic acid receptor 3Homo sapiens (human)
plasma membraneHydroxycarboxylic acid receptor 3Homo sapiens (human)
plasma membraneHydroxycarboxylic acid receptor 2Homo sapiens (human)
cell junctionHydroxycarboxylic acid receptor 2Homo sapiens (human)
plasma membraneHydroxycarboxylic acid receptor 2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (70)

Assay IDTitleYearJournalArticle
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID281256Activity at GPR109b in CHO cells assessed as inhibition of forskolin-induced cAMP generation2007Journal of medicinal chemistry, Apr-05, Volume: 50, Issue:7
Analogues of acifran: agonists of the high and low affinity niacin receptors, GPR109a and GPR109b.
AID172355Effect on serum Triglycerides was determined in normal rats at a dose of 0.1 (mmol/kg)/day1982Journal of medicinal chemistry, Oct, Volume: 25, Issue:10
Hypolipidemic 4,5-dihydro-4-oxo-5,5-disubstituted-2-furancarboxylic acids.
AID190946Effect on serum Triglycerides levels was measured on control rats at a dose of 0.05 (mmol/kg)/day1982Journal of medicinal chemistry, Oct, Volume: 25, Issue:10
Hypolipidemic 4,5-dihydro-4-oxo-5,5-disubstituted-2-furancarboxylic acids.
AID172354Effect on serum Triglycerides was determined in normal rats at a dose of 0.03 (mmol/kg)/day1982Journal of medicinal chemistry, Oct, Volume: 25, Issue:10
Hypolipidemic 4,5-dihydro-4-oxo-5,5-disubstituted-2-furancarboxylic acids.
AID281255Activity at GPR109a in CHO cells assessed as inhibition of forskolin-induced cAMP generation2007Journal of medicinal chemistry, Apr-05, Volume: 50, Issue:7
Analogues of acifran: agonists of the high and low affinity niacin receptors, GPR109a and GPR109b.
AID428324Agonist activity at N-terminal HA-tagged GPR109b receptor transfected in forskolin-stimulated cells assessed as cAMP accumulation by flashplate assay2009Bioorganic & medicinal chemistry letters, Aug-01, Volume: 19, Issue:15
5-N,N-Disubstituted 5-aminopyrazole-3-carboxylic acids are highly potent agonists of GPR109b.
AID186011Effect on liver weight was measured on treated rats at a dose of 0.5 (mmol/kg)/day1982Journal of medicinal chemistry, Oct, Volume: 25, Issue:10
Hypolipidemic 4,5-dihydro-4-oxo-5,5-disubstituted-2-furancarboxylic acids.
AID172353Effect on serum Triglycerides was determined in normal rats at a dose of 0.02 (mmol/kg)/day1982Journal of medicinal chemistry, Oct, Volume: 25, Issue:10
Hypolipidemic 4,5-dihydro-4-oxo-5,5-disubstituted-2-furancarboxylic acids.
AID1232300Agonist activity at HCA3 receptor (unknown origin) expressed in CHOK1 cells assessed as ERK1/2 phosphorylation by ELISA2015Bioorganic & medicinal chemistry, Jul-15, Volume: 23, Issue:14
Affinity and kinetics study of anthranilic acids as HCA2 receptor agonists.
AID172351Effect on serum Triglycerides was determined in normal rats at a dose of 0.005 (mmol/kg)/day1982Journal of medicinal chemistry, Oct, Volume: 25, Issue:10
Hypolipidemic 4,5-dihydro-4-oxo-5,5-disubstituted-2-furancarboxylic acids.
AID190947Effect on serum Triglycerides levels was measured on control rats at a dose of 0.5 (mmol/kg)/day1982Journal of medicinal chemistry, Oct, Volume: 25, Issue:10
Hypolipidemic 4,5-dihydro-4-oxo-5,5-disubstituted-2-furancarboxylic acids.
AID172357Effect on serum Triglycerides was determined in normal rats at a dose of 1 (mmol/kg)/day1982Journal of medicinal chemistry, Oct, Volume: 25, Issue:10
Hypolipidemic 4,5-dihydro-4-oxo-5,5-disubstituted-2-furancarboxylic acids.
AID190949Effect on serum Triglycerides levels was measured on treated rats at a dose of 0.5 (mmol/kg)/day1982Journal of medicinal chemistry, Oct, Volume: 25, Issue:10
Hypolipidemic 4,5-dihydro-4-oxo-5,5-disubstituted-2-furancarboxylic acids.
AID172356Effect on serum Triglycerides was determined in normal rats at a dose of 0.2 (mmol/kg)/day1982Journal of medicinal chemistry, Oct, Volume: 25, Issue:10
Hypolipidemic 4,5-dihydro-4-oxo-5,5-disubstituted-2-furancarboxylic acids.
AID172352Effect on serum Triglycerides was determined in normal rats at a dose of 0.01 (mmol/kg)/day1982Journal of medicinal chemistry, Oct, Volume: 25, Issue:10
Hypolipidemic 4,5-dihydro-4-oxo-5,5-disubstituted-2-furancarboxylic acids.
AID1232297Agonist activity at HCA2 receptor (unknown origin) expressed in Saccharomyces cerevisiae MMY24 assessed as growth rate of yeast on histidine deficient medium at 100 uM by FUS1-HIS3 reporter gene assay2015Bioorganic & medicinal chemistry, Jul-15, Volume: 23, Issue:14
Affinity and kinetics study of anthranilic acids as HCA2 receptor agonists.
AID1232298Agonist activity at HCA3 receptor (unknown origin) expressed in Saccharomyces cerevisiae MMY24 assessed as growth rate of yeast on histidine deficient medium at 100 uM by FUS1-HIS3 reporter gene assay2015Bioorganic & medicinal chemistry, Jul-15, Volume: 23, Issue:14
Affinity and kinetics study of anthranilic acids as HCA2 receptor agonists.
AID1232299Agonist activity at HCA2 receptor (unknown origin) expressed in CHOK1 cells assessed as ERK1/2 phosphorylation by ELISA2015Bioorganic & medicinal chemistry, Jul-15, Volume: 23, Issue:14
Affinity and kinetics study of anthranilic acids as HCA2 receptor agonists.
AID388795Activity at GPR109b assessed as inhibition of forskolin-stimulated cAMP production2008Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
Nicotinic acid receptor agonists.
AID388794Activity at GPR109a assessed as inhibition of forskolin-stimulated cAMP production2008Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
Nicotinic acid receptor agonists.
AID186010Effect on liver weight was measured on treated rats at a dose of 0.05 (mmol/kg)/day1982Journal of medicinal chemistry, Oct, Volume: 25, Issue:10
Hypolipidemic 4,5-dihydro-4-oxo-5,5-disubstituted-2-furancarboxylic acids.
AID281258Activity at GPR109b in CHO cells assessed as inhibition of forskolin-induced cAMP generation upto 100 uM2007Journal of medicinal chemistry, Apr-05, Volume: 50, Issue:7
Analogues of acifran: agonists of the high and low affinity niacin receptors, GPR109a and GPR109b.
AID227699Virtual screen for compounds with anticonvulsant activity2003Bioorganic & medicinal chemistry letters, Aug-18, Volume: 13, Issue:16
Topological virtual screening: a way to find new anticonvulsant drugs from chemical diversity.
AID281260Activity at GPR109a in CHO cells assessed as inhibition of forskolin-induced cAMP generation upto 100 uM2007Journal of medicinal chemistry, Apr-05, Volume: 50, Issue:7
Analogues of acifran: agonists of the high and low affinity niacin receptors, GPR109a and GPR109b.
AID190948Effect on serum Triglycerides levels was measured on treated rats at a dose of 0.05 (mmol/kg)/day1982Journal of medicinal chemistry, Oct, Volume: 25, Issue:10
Hypolipidemic 4,5-dihydro-4-oxo-5,5-disubstituted-2-furancarboxylic acids.
AID186008Effect on liver weight was measured on control rats at a dose of 0.05 (mmol/kg)/day1982Journal of medicinal chemistry, Oct, Volume: 25, Issue:10
Hypolipidemic 4,5-dihydro-4-oxo-5,5-disubstituted-2-furancarboxylic acids.
AID428325Agonist activity at N-terminal HA-tagged GPR109a receptor transfected in forskolin-stimulated cells assessed as cAMP accumulation by flashplate assay2009Bioorganic & medicinal chemistry letters, Aug-01, Volume: 19, Issue:15
5-N,N-Disubstituted 5-aminopyrazole-3-carboxylic acids are highly potent agonists of GPR109b.
AID186009Effect on liver weight was measured on control rats at a dose of 0.5 (mmol/kg)/day1982Journal of medicinal chemistry, Oct, Volume: 25, Issue:10
Hypolipidemic 4,5-dihydro-4-oxo-5,5-disubstituted-2-furancarboxylic acids.
AID281259Selectivity for GPR109a over GPR109b2007Journal of medicinal chemistry, Apr-05, Volume: 50, Issue:7
Analogues of acifran: agonists of the high and low affinity niacin receptors, GPR109a and GPR109b.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347424RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347425Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347407qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1346334Human HCA3 receptor (Hydroxycarboxylic acid receptors)2007Journal of medicinal chemistry, Apr-05, Volume: 50, Issue:7
Analogues of acifran: agonists of the high and low affinity niacin receptors, GPR109a and GPR109b.
AID1346334Human HCA3 receptor (Hydroxycarboxylic acid receptors)2005The Journal of biological chemistry, Jul-22, Volume: 280, Issue:29
(D)-beta-Hydroxybutyrate inhibits adipocyte lipolysis via the nicotinic acid receptor PUMA-G.
AID1346416Human HCA2 receptor (Hydroxycarboxylic acid receptors)2003The Journal of biological chemistry, Mar-14, Volume: 278, Issue:11
Molecular identification of high and low affinity receptors for nicotinic acid.
AID1346416Human HCA2 receptor (Hydroxycarboxylic acid receptors)2007Journal of medicinal chemistry, Apr-05, Volume: 50, Issue:7
Analogues of acifran: agonists of the high and low affinity niacin receptors, GPR109a and GPR109b.
AID1346334Human HCA3 receptor (Hydroxycarboxylic acid receptors)2006Biochemical and biophysical research communications, Feb-10, Volume: 340, Issue:2
Triglyceride modulation by acifran analogs: activity towards the niacin high and low affinity G protein-coupled receptors HM74A and HM74.
AID1346416Human HCA2 receptor (Hydroxycarboxylic acid receptors)2005The Journal of biological chemistry, Jul-22, Volume: 280, Issue:29
(D)-beta-Hydroxybutyrate inhibits adipocyte lipolysis via the nicotinic acid receptor PUMA-G.
AID1346334Human HCA3 receptor (Hydroxycarboxylic acid receptors)2003The Journal of biological chemistry, Mar-14, Volume: 278, Issue:11
Molecular identification of high and low affinity receptors for nicotinic acid.
AID1346416Human HCA2 receptor (Hydroxycarboxylic acid receptors)2006Biochemical and biophysical research communications, Feb-10, Volume: 340, Issue:2
Triglyceride modulation by acifran analogs: activity towards the niacin high and low affinity G protein-coupled receptors HM74A and HM74.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (29)

TimeframeStudies, This Drug (%)All Drugs %
pre-19908 (27.59)18.7374
1990's2 (6.90)18.2507
2000's8 (27.59)29.6817
2010's4 (13.79)24.3611
2020's7 (24.14)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 23.07

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index23.07 (24.57)
Research Supply Index3.47 (2.92)
Research Growth Index4.89 (4.65)
Search Engine Demand Index23.28 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (23.07)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials2 (6.90%)5.53%
Reviews2 (6.90%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other25 (86.21%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]